Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.
| Image |  |
|---|---|
| Description | scientific article published on 21 February 2018 |
| Author/s | |
| Publication date | March 15, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |